2096.HK
SIMCERE PHARMA
HK$9.97
+2.15%
2026-05-29
About SIMCERE PHARMA
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN simnotrelvir tablets and ritonavir tablets. The company also offers promotional services for pharmaceutical products. In addition, it engages in the manufacture of pharmaceutical ingredients and its property management business. The company has a partnership with Connect Biopharma Hong Kong Limited to jointly develop Rademikibart, a human monoclonal antibody. The company was founded in 1995 and is headquartered in Nanjing, China.
Key Fundamentals
P/E Ratio
19.29
Forward P/E
13.98
EPS (TTM)
HK$0.62
ROE
16.2%
Revenue Growth (YoY)
17.7%
Profit Margin
17.4%
Debt/Equity
12.61
Dividend Yield
1.7%
Price/Book
2.87
Beta
0.73
Market Cap
HK$30.86B
Avg Volume (10D)
4.0M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
HK$14.28
60D Low
HK$9.60
Avg Volume
6.9M
Latest Close
HK$9.97
Get breakout alerts for 2096.HK
Sign up for Breakout Scanner to receive daily notifications when 2096.HK triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
SIMCERE PHARMA (2096.HK) is listed on the Hong Kong Exchanges (HKEX). Breakout Scanner monitors 2096.HK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 2096.HK operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry. Data is provided for informational purposes only and does not constitute financial advice.